FibroBiologics, Inc. (FBLG) Cash Flow Statement
Where FBLG’s cash came from and went, FY2026
June 30, 2026 · U.S. dollars- Cash from operations
- −$16.4M
- Capital expenditures
- $262,000
- Free cash flow
- −$16.7M
- Returned to shareholders
- —
- Change in cash
- −$9.1M cash at year-end $4.9M
Drawn to scale: where the cash came from and how it was used. Hover for values.
FBLG operating cash flow, capex and free cash flow
FBLG cash flow trends, FY2021–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$1.2MFY2021 | −$16.4MFY2026 | — | |
| Capital expenditures | $0FY2021 | $262,000FY2026 | — | |
| Free cash flow | −$1.2MFY2021 | −$16.7MFY2026 | — | |
| Stock-based compensation | $0FY2022 | $2.7MFY2026 | — |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
FBLG cash flow by activity
FBLG net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
FBLG cash flow statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Operating activities | ||||||
| Net income | −$18.6M | −$11.2M | −$16.5M | −$5.1M | −$1.6M | −$1.2M |
| Depreciation & amortization | $832,000 | $573,000 | $437,000 | $94,000 | $0 | — |
| Stock-based compensation | $2.7M | $2.2M | $1.8M | $265,000 | $0 | — |
| Change in working capital | −$3.3M | $559,000 | $493,000 | $307,000 | $172,000 | — |
| Other non-cash items | $2.0M | −$4.1M | $7.4M | $389,000 | $0 | $0 |
| Cash from operating activities | −$16.4M | −$11.9M | −$6.4M | −$4.1M | −$1.4M | −$1.2M |
| Investing activities | ||||||
| Capital expenditures | −$262,000 | −$184,000 | −$495,000 | $0 | $0 | $0 |
| Investments (net) | — | −$184,000 | −$495,000 | $0 | — | — |
| Acquisitions & other investing | $0 | $184,000 | $495,000 | — | — | — |
| Cash from investing activities | −$262,000 | −$184,000 | −$495,000 | — | — | — |
| Financing activities | ||||||
| Net borrowing (repayment) | $975,000 | $9.4M | $300,000 | $3.8M | $1.5M | — |
| Shares issued | $6.6M | $7.5M | $16.1M | $2.1M | $0 | $0 |
| Other financing | $0 | $0 | −$2.6M | $0 | $292,000 | $1.2M |
| Cash from financing activities | $7.6M | $16.9M | $13.8M | $5.9M | $1.8M | $1.2M |
| Summary | ||||||
| Net change in cash | −$9.1M | $4.8M | $6.9M | $1.9M | $407,000 | — |
| Cash at end of period | $4.9M | $14.0M | $9.2M | $2.3M | $407,000 | — |
| Free cash flow | −$16.7M | −$12.1M | −$6.9M | −$4.1M | −$1.4M | −$1.2M |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$4.1M | −$5.0M | −$3.2M | −$5.8M | −$4.7M | −$5.0M | −$3.1M | −$500,000 | $898,000 | −$8.5M | −$9.7M | −$2.2M |
| Depreciation & amortization | $161,000 | $237,000 | $234,000 | $231,000 | $206,000 | $161,000 | $153,000 | $143,000 | $140,000 | $137,000 | $130,000 | $112,000 |
| Stock-based compensation | $707,000 | $694,000 | $702,000 | $704,000 | $729,000 | $551,000 | $544,000 | $571,000 | $578,000 | $525,000 | $432,000 | $437,000 |
| Change in working capital | −$10,000 | −$241,000 | −$1.3M | $58,000 | −$479,000 | −$1.6M | −$279,000 | −$44,000 | $463,000 | $419,000 | $318,000 | $504,000 |
| Other non-cash items | −$32,000 | −$54,000 | $481,000 | $813,000 | $218,000 | $534,000 | −$392,000 | −$2.8M | −$4.0M | $3.1M | $7.2M | $0 |
| Cash from operating activities | −$3.3M | −$4.4M | −$3.2M | −$4.0M | −$4.0M | −$5.3M | −$3.1M | −$2.6M | −$1.9M | −$4.3M | −$1.6M | −$1.1M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | $0 | $0 | −$6,000 | −$213,000 | −$43,000 | −$99,000 | −$11,000 | −$66,000 | −$8,000 | −$2,000 | −$413,000 |
| Investments (net) | — | — | — | −$6,000 | −$213,000 | −$43,000 | −$99,000 | −$11,000 | −$66,000 | −$8,000 | −$2,000 | −$413,000 |
| Acquisitions & other investing | — | — | — | $6,000 | $213,000 | $43,000 | $99,000 | $11,000 | $66,000 | $8,000 | $2,000 | $413,000 |
| Cash from investing activities | — | — | — | −$6,000 | −$213,000 | −$43,000 | −$99,000 | −$11,000 | −$66,000 | −$8,000 | −$2,000 | −$413,000 |
| Financing activities | ||||||||||||
| Net borrowing (repayment) | −$122,000 | $246,000 | −$3.4M | $0 | $4.4M | $0 | $9.3M | −$172,000 | — | — | — | — |
| Shares issued | $2.9M | $706,000 | $6.6M | $0 | $0 | $0 | $45,000 | $4.6M | $0 | $2.8M | $0 | $940,000 |
| Other financing | $2.6M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | −$172,000 | $459,000 | $0 | $0 |
| Cash from financing activities | $5.3M | $952,000 | $3.2M | $0 | $4.4M | $0 | $9.3M | $4.5M | −$172,000 | $3.3M | $0 | $940,000 |
| Summary | ||||||||||||
| Net change in cash | $2.0M | −$3.4M | $27,000 | −$4.0M | $178,000 | −$5.3M | $6.2M | $1.9M | −$2.2M | −$1.0M | −$1.6M | −$612,000 |
| Cash at end of period | $3.5M | $1.5M | $4.9M | $4.9M | $8.8M | $8.7M | $14.0M | $7.8M | $6.0M | $8.2M | $9.2M | $10.8M |
| Free cash flow | −$3.3M | −$4.4M | −$3.2M | −$4.0M | −$4.2M | −$5.3M | −$3.2M | −$2.6M | −$2.0M | −$4.3M | −$1.6M | −$1.6M |
| Free cash flow margin | — | — | — | — | — | — | −572.6% | — | — | — | — | — |
| Capex / revenue | — | — | — | — | — | — | 17.9% | — | — | — | — | — |
| Operating cash flow / net income | — | — | — | — | — | — | — | — | −2.17 | — | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
FBLG cash generation
In fiscal 2026 (ended June 30, 2026), FibroBiologics generated -$16.4 million of cash from operations and spent $0.3 million on capital expenditures, leaving free cash flow of -$16.7 million. Cash and equivalents fell by $9.1 million over the year.
Related: FBLG income statement, FBLG balance sheet. See the FBLG stock overview for the latest quote and news.
FBLG cash flow FAQ
What is FibroBiologics's free cash flow?
FibroBiologics's free cash flow was -$16.7 million in fiscal 2026: -$16.4 million of operating cash flow minus $0.3 million of capital expenditures It was -$12.1 million a year earlier..
How much cash does FibroBiologics generate from operations?
FibroBiologics generated -$16.4 million of cash from operating activities in fiscal 2026.
How much does FibroBiologics spend on capital expenditures?
FibroBiologics spent $0.3 million on capital expenditures in fiscal 2026, compared with $0.2 million the year before.